See the Complete Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Memorial Day
French Open
Artificial Intelligence
European Union
Social Media
Education
Work
Money
Infrastructure
Donald Trump
Stock Markets
Taxes
Published • loading... • Updated

UroGen Downgrade After FDA Setback For Bladder Cancer Drug - UroGen Pharma (NASDAQ:URGN)

Summary by Benzinga
Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.

1 Articles

All
Left
Center
1
Right
BenzingaBenzinga
Center

UroGen Downgrade After FDA Setback For Bladder Cancer Drug - UroGen Pharma (NASDAQ:URGN)

Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Sunday, May 25, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

News
For You
SearchBlindspotLocal